Table 2.
Quality indicators rating and ranking based on expert panel review
| QI | Abbreviated quality indicators | Validity rating (1–9) | Rank on validity scale (1–36) | Feasibility average rank | Rank on feasibility scale (1–36) | Level of evidence weighting of evidencea |
|---|---|---|---|---|---|---|
| 01 | Antiplatelet therapy (aspirin) | 8.92 | 1 | 3.67 | 1 | A/I |
| 25 | ACE for CHF | 8.75 | 2 | 5.42 | 3 | A/I |
| 15 | ACE or ARBs w/impaired renal fx (proteinuria) | 8.58 | 3 | 11.5 | 9 | A/I |
| 10 | Smoking status documented | 8.50 | 4 | 7.25 | 4 | B |
| 16 | BP control for diabetes with hypertension | 8.50 | 5 | 8.50 | 5 | A |
| 05 | Beta-blockers post-MI | 8.42 | 6 | 5.00 | 2 | A/I |
| 06 | ACE w/low EF, CHF or diabetes | 8.42 | 7 | 9.00 | 7 | A/I |
| 23 | Complete lipid profile ordered (post-MI) | 8.17 | 8 | 9.83 | 8 | A |
| 13 | Monitor HbA1C in diabetics | 8.08 | 9 | 12.00 | 10 | B |
| 11 | Smoking counseling | 8.08 | 10 | 16.08 | 12 | B |
| 27 | Beta-blockers for CHF | 7.92 | 11 | 16.67 | 14 | A/I |
| 08 | Statin therapy for LDL | 7.83 | 12 | 8.83 | 6 | A/I |
| 30 | Diuretics in CHF w/edema | 7.83 | 13 | 14.58 | 11 | A |
| 14 | Glycemic control intervention for diabetes | 7.75 | 14 | 17.50 | 15 | B |
| 24 | Annual lipid profiles (follow-up) | 7.75 | 15 | 18.75 | 16 | A |
| 19 | Annual eye examination in diabetics | 7.75 | 16 | 19.50 | 18 | Not specified |
| 36 | No HRT prescribed | 7.75 | 17 | 28.67 | 35 | IIa |
| 34 | Weight loss consultation | 7.67 | 18 | 25.25 | 26 | B |
| 33 | Assess for risk of depression | 7.67 | 19 | 26.92 | 30 | Not specified |
| 21 | BB and ACE as first-line therapy in HTN | 7.42 | 20 | 21.75 | 23 | B |
| 18 | Annual influenza vaccinations in diabetics | 7.33 | 21 | 16.58 | 13 | Not specified |
| 35 | Risk of HRT discussed | 7.33 | 22 | 29.25 | 36 | Not specified |
| 20 | Annual foot examination in diabetics | 7.25 | 23 | 19.42 | 17 | Not specified |
| 28 | Calcium channel blockers in CHF | 7.17 | 24 | 27.08 | 31 | Not specified |
| 02 | Antiplatelet therapy (Clopidogrel) | 7.08 | 25 | 20.33 | 21 | A/I |
| 32 | Monitor serum K+ w/dig/diuretics in combination | 7.00 | 26 | 22.33 | 24 | Not specified |
| 31 | Spironolactone for Classes III/IV CHF | 7.00 | 27 | 23.58 | 25 | Not specified |
| 12 | Nicotine replacement therapy in smokers | 6.92 | 28 | 27.17 | 32 | Not specified |
| 04 | Antiplatelet therapy (Warfarin and antiplatelet drugs) | 6.67 | 29 | 25.42 | 28 | Not specified |
| 03 | Antiplatelet therapy (Warfarin) | 6.5 | 30 | 20.00 | 19 | I, IIa, IIb |
| 26 | ARBs for CHF when ACE contraindicated | 6.33 | 31 | 20.50 | 22 | Not specified |
| 09 | Monitor CK in combination lipid lowering therapy | 6.25 | 32 | 25.83 | 29 | Not specified |
| 07 | ACE without low EF, CHF or diabetes | 6.17 | 33 | 20.25 | 20 | A |
| 17 | Monitor serum creatinine q 6mos in HTN | 6.00 | 34 | 25.25 | 27 | Not specified |
| 22 | Assess pt adherence in uncontrolled HTN | 6.00 | 35 | 28.08 | 33 | Not specified |
| 29 | Monitor dig levels in renal failure | 5.92 | 36 | 28.25 | 34 | Not specified |
aIn abstracting recommendations from MI-Plus guidelines, we considered the evidence rankings (A, B, C) and the ACC/AHA classifications (classes I, II, III) when assigned or provided by the guideline.